An update on the topical and oral therapy options for treating pediatric atopic dermatitis

Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood

“…The therapeutic arsenal available for 0-to 12-year-old patients with AD is limited to topical agents, broad systemic immune suppressants, or both. 4,18 Active development of targeted therapeutics is ongoing for adults and adolescents with AD and will eventually move to children, further necessitating the elucidation of pediatric endotypes at successive preadult age groups to introduce safe, effective, and age-tailored targeted approaches. 19 We compared T-cell memory subset activation and polarized CD4/CD8 subset frequencies within the skin-homing/cutaneous lymphocyte antigen (CLA) 1 and systemic/CLA 2 compartments in the blood of infants and toddlers (0-5 years old), young children (6 to 11 years old), adolescents (12 to 17 years old), and adults (> _18 years old) with moderate-to-severe AD.…”

Recent Modalities in Treatment of Atopic Dermatitis: Review Article

“…Only in the most severe cases of AD should it be considered for usage in children and adolescents. Individual cohort and randomized controlled trials data are used to make recommendations for use in children (31) .…”

Approach to the Assessment and Management of Pediatric Patients With Atopic Dermatitis: A Consensus Document. Section III: Treatment Options for Pediatric Atopic Dermatitis

“…34 TCS are anti-inflammatory and anti-pruritic agents that act nonspecifically to suppress the release of pro-inflammatory cytokines. [34][35][36] They have a fast onset of action 37 and can be used to treat acute flares or as maintenance therapy. 34,35 Proactive maintenance therapy with intermittent TCS plus emollient can reduce recurrence of flares 38 and may prevent sensitization to aeroallergens in pediatric AD.…”

“…[34][35][36] They have a fast onset of action 37 and can be used to treat acute flares or as maintenance therapy. 34,35 Proactive maintenance therapy with intermittent TCS plus emollient can reduce recurrence of flares 38 and may prevent sensitization to aeroallergens in pediatric AD. 39 TCS are classified based on potency.…”